MART-1 + Tyrosinase + SOX10 – Primary Antibodies
Price range: $295.00 through $813.00
Description
Product Description
MART-1 recognizes an 18 kDa protein (Melanoma Antigen Recognized by T cells 1) and is specific for melanocytic lesions, making it a valuable component of melanoma panels.15-17 MART-1 has been shown to be more sensitive than HMB45 for labeling metastatic melanomas. Tyrosinase, a key enzyme in early melanin biosynthesis, is more sensitive than HMB45 and MART-1 and labels a higher percentage of desmoplastic melanomas.15 The combination of MART-1 and Tyrosinase aids in identifying metastatic melanoma in sentinel lymph nodes.16
SOX10, a transcription factor in the SRY-related HMG-Box family, plays an important role in neural crest, peripheral nervous system, and melanocytic cell development.18-22 It is widely expressed in normal human tissues including melanocytes and breast tissue and is a marker for malignant tumors such as melanoma, breast carcinoma, gliomas, and benign tumors including schwannomas.18-20 SOX10 is expressed in the vast majority of desmoplastic and spindle cell melanomas and in 100% of nevi.18,19 Compared to S100, SOX10 is less likely to stain background fibroblasts or histiocytes within scars, making it a more specific marker in these contexts.20
The combination of SOX10 with MART-1 and/or Tyrosinase increases detection sensitivity in lymph node and metastatic melanoma specimens compared to S100 and provides greater specificity, as S100 stains dendritic processes in lymph nodes while SOX10, MART-1, and Tyrosinase remain negative.21,22 This antibody cocktail is suitable for tumors of unknown origin or for differential diagnosis of melanoma and its mimics. PATENT PENDING.
Specifications
Specifications
| Intended Use | |
|---|---|
| Format | |
| Volume | |
| Antigen | |
| Species Reactivity | |
| Isotype | |
| Source | |
| Positive Control |
Datasheets & SDS
| Download CE Marked IVD Datasheet |
| Download IVD Datasheet Without CE Mark |
| Download RUO Datasheet |
| Download SDS Sheet |
Browse more documents for this product (IFUs, datasheets, translations, SDS, and more).
References
1. Orchard G. Evaluation of melanocytic neoplasms: application of a pan-melanoma antibody cocktail. Br J Biomed Sci. 2002;59(4):196-202.
2. Cook MG, et al. The development of optimal pathological assessment of sentinel lymph nodes for melanoma. J Pathol. 2003 Jul;200(3):314-9.
3. Blessing K, Sanders DS, Grant JJ. Comparison of immunohistochemical staining of the novel antibody Melan-A with S100 protein and HMB-45 in malignant melanoma
and melanoma variants. Histopathology. 1998 Feb; 32 (2):139-46.
4. Mohamed A, et al. SOX10 Expression in malignant melanoma, carcinoma, and normal tissues. Appl Immunohistochem Mol Morphol. 2013 Dec; 21(6):506-10.
5. Mollaaghababa R, Pavan WJ. The importance of having your SOX on: role of SOX10 in the development of neural crest-derived melanocytes and glia. Oncogene.
2003 May 19; 22(20):3024-34.
6. Tacha D, et al. A newly developed mouse monoclonal SOX10 antibody is a highly sensitive and specific marker for malignant melanoma, including spindle cell and desmoplastic melanomas. Arch Pathol Lab Med. 2015 Apr;139(4):530-6.
7. Tacha D, et al. An Immunohistochemical Comparison Study of SOX10, Pan Melanoma Cocktail and S100 in Malignant Melanoma. American Society of Dermatopathology, 51st Annual Meeting; Poster #278, Nov 6, 2014.
8. Willis BC, et al. SOX10: a useful marker for identifying metastatic melanoma in sentinel lymph nodes. Appl Immunohistochem Mol Morphol. 2015 Feb;23(2):109-12.
9. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
10. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.
